|
Immunovant, Inc. (IMVT) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Immunovant, Inc. (IMVT) Bundle
Gain insight into your Immunovant, Inc. (IMVT) valuation analysis with our sophisticated DCF Calculator! This Excel template comes preloaded with real IMVT data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Immunovant, Inc.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -65.6 | -106.8 | -155.6 | -209.6 | -270.0 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .0 | 1.0 | 1.2 | 1.3 | .2 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -65.7 | -107.8 | -156.8 | -211.0 | -270.2 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 100.6 | 400.1 | 493.8 | 376.5 | 635.4 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 3.0 | 1.1 | 12.9 | .9 | 5.5 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 1.2 | 2.4 | 18.6 | 1.4 | 7.2 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.2 | -.3 | -.2 | -.4 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -0.21911 | -0.21911 | -0.21911 | -0.21911 | -0.21911 | -0.21911 | -0.21911 | -0.21911 | -0.21911 | -0.21911 |
| EBITAT | -65.8 | -107.4 | -156.7 | -211.0 | -270.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -67.6 | -103.5 | -151.3 | -215.1 | -269.7 | -1.7 | .0 | .0 | .0 | .0 |
| WACC, % | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -635 | |||||||||
| Equity Value | 634 | |||||||||
| Diluted Shares Outstanding, MM | 138 | |||||||||
| Equity Value Per Share | 4.59 |
What You Will Get
- Real IMVT Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust discount rates, tax implications, revenue forecasts, and capital investments.
- Dynamic Calculations: Intrinsic value and NPV are automatically computed in real-time.
- Scenario Analysis: Explore various scenarios to assess Immunovant’s future growth.
- User-Friendly Design: Crafted for industry experts while remaining approachable for newcomers.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Immunovant, Inc. (IMVT).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to Immunovant, Inc. (IMVT).
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates relevant to Immunovant, Inc. (IMVT).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Immunovant, Inc. (IMVT).
- Interactive Dashboard and Charts: Visual representations summarize key valuation metrics for straightforward analysis of Immunovant, Inc. (IMVT).
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Immunovant, Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions regarding Immunovant, Inc. (IMVT).
Why Choose Immunovant, Inc. (IMVT)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Strong Pipeline: Robust development pipeline focused on autoimmune diseases.
- Expert Team: Led by industry veterans with extensive experience in biopharmaceuticals.
- Commitment to Patients: Driven by a mission to improve the lives of those affected by chronic conditions.
- Proven Track Record: Backed by successful clinical trials and positive outcomes.
Who Should Use This Product?
- Investors: Accurately assess Immunovant, Inc.'s (IMVT) fair value prior to making investment choices.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis specific to Immunovant, Inc. (IMVT).
- Consultants: Efficiently customize the template for valuation reports tailored to Immunovant, Inc. (IMVT) clients.
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading biopharmaceutical companies.
- Educators: Implement it as a teaching resource to illustrate valuation techniques in the biotech sector.
What the Template Contains
- Preloaded IMVT Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.